Rhythm Biosciences Limited

Commercialisation is about more than launching a product; it's about building the evidence, infrastructure and clinical confidence needed to support adoption. Today's announcement marks another important milestone in Rhythm Biosciences' commercial strategy for ColoSTAT®. Following extensive engagement with GPs, gastroenterologists and colorectal surgeons across Australia, we've confirmed two key commercial insights: ✔️ Colonoscopy capacity remains under significant pressure. ✔️ General Practitioners are the primary referral pathway for patients presenting with bowel cancer symptoms. These findings have directly informed the launch of our first large-scale GP awareness campaign through Australian Doctor Group, designed to reach more than 20,000 authenticated GPs across Australia's eastern states with evidence-based educational content supporting the appropriate use of ColoSTAT®. Importantly, this campaign doesn't stand alone. It builds on the commercial foundations we've established over recent months, including: • our expanded partnership with 4Cyte Pathology • the growing ColoSTAT® Access Programme (CAP) • Medical Science Liaison engagement with clinicians • expansion of collection centre access into regional Australia • ongoing education initiatives across primary care. Together, these initiatives represent a coordinated commercialisation strategy focused on building clinician awareness, supporting appropriate patient access, and generating the real-world experience needed to drive sustainable adoption of ColoSTAT®. We're excited to continue building momentum as we execute our strategy and look forward to sharing further updates as the campaign progresses. Read today's ASX announcement : https://lnkd.in/gE9Q9C6R #RhythmBiosciences #ColoSTAT #Diagnostics #ColorectalCancer #PrimaryCare #4Cyte #AusDoc #HealthcareInnovation #MedicalDiagnostics #AustralianHealthcare

As Bowel Cancer Awareness Month is ending soon, we believe you should be aware throughout the year not only in June. Bowel cancer is Australia's second leading cause of cancer death. Most cases are found because someone raised symptoms with their doctor. That conversation matters. So does what happens next. We've published a plain-language guide to the diagnostic pathway — what to expect, why it takes time, and what options now exist. To learn more and read our blog article, click https://lnkd.in/gDsMzRJ7 To learn more about bowel cancer, visit Bowel Cancer Australia https://lnkd.in/fidyqcK or https://www.colostat.com #BowelCancerAwarenessMonth #BowelCancer #EarlyDetection #ColoSTAT #RhythmBiosciences #Referral #Diagnosticjourney

🩸 This Bowel Cancer Awareness Month, we've partnered with AusDoc to get ColoSTAT® in front of doctors that need to know. Bowel cancer is Australia's second leading cause of cancer death. Early detection saves lives. Yet right now, thousands of patients are waiting too long for the colonoscopy that could change everything. That's exactly the problem ColoSTAT® was built to solve — a simple blood test to help GPs assess which patients need urgent investigation. Starting this month, we're proud to share that Rhythm Biosciences has partnered with AusDoc — one of Australia's most trusted platforms for General Practitioners — to bring this conversation directly to primary care. 📖 If you are a GP and registered with AusDoc? Read the full article: https://lnkd.in/deuJMQna 🔬 Not registered with AusDoc? Learn more about how ColoSTAT® is supporting bowel cancer detection, visit colostat.com Bowel cancer awareness month may be winding down — but the urgency around early detection never does. #BowelCancerAwarenessMonth #ColoSTAT #EarlyDetection #ColorectalCancer #BowelCancer #GPs #PrimaryCare #AusDoc #RhythmBiosciences #HealthcareInnovation #CancerDetection

🎥 ColoSTAT: Diagnosing Commercial Growth: Commercialisation momentum continues to build for ColoSTAT through two complementary but distinct programs: our commercial sales activities and the Clinical Access Program (CAP). In this latest update, RHY CEO Dr David Atkins discusses how we are driving awareness and adoption through GP education, digital marketing initiatives, conference engagement and direct business development activities, while simultaneously expanding patient access through the CAP. Importantly, the CAP is not only providing broader access to ColoSTAT but is also generating valuable real-world data, including an initial assessment of the economic impact of the program. We look forward to sharing the findings from this health economics work in the coming weeks, adding another important layer to our understanding of ColoSTAT's potential value within the healthcare system. As we continue to build awareness, gather feedback and expand adoption, we're focused on creating a strong foundation for long-term commercial growth. 🎥 Watch the full video below. #ColoSTAT #MedicalDiagnostics #HealthcareInnovation #ASX #RHY #CancerDiagnostics #Commercialisation #Biotechnology #HealthEconomics #ColorectalCancer #InvestorUpdate

This week, Rhythm Biosciences is in Singapore meeting with investors and industry stakeholders as part of our ongoing efforts to support the Company's growth and long-term success. While there is no new material information to report, these meetings provide an important opportunity to discuss the progress Rhythm has made in recent months, including our commercial rollout initiatives, market opportunities and strategic priorities as we continue our transition to a fully commercial diagnostics company. One of our key objectives is ensuring the Rhythm story is understood by a broader audience of investors and healthcare stakeholders. Building these relationships today helps create opportunities for the future and increases awareness of the significant market opportunity ahead of us. To learn more about our progress and strategy, please view our latest investor presentation released to the ASX via the link below. 🔗 https://lnkd.in/gVMkqqJQ #RhythmBiosciences #ColoSTAT #Diagnostics #Biotech #HealthcareInnovation #ASX

📢 Clinical Momentum Continues to Build as Rhythm Secures Further Clinician Support for Colostat®. Inc. Senior gastroenterologists and surgeons across Australia. For diagnostics, this is where commercial adoption starts 🦾 Today we announce a further 16 clinicians are now enrolled in the ColoSTAT® Clinical Access Program across Australia. Importantly, the Program is attracting senior gastroenterologists and surgeons - reinforcing growing clinical confidence in ColoSTAT® as a frontline colorectal cancer triage tool. This is what commercial execution looks like in diagnostics. Commercial adoption starts with: → clinician engagement → workflow integration → real-world evidence → reimbursement pathways As clinician participation continues expanding nationally, Rhythm Biosciences is strengthening the commercial foundations for broader market adoption of ColoSTAT®. #ASX #RHY #Biotech #Diagnostics #Healthcare

As part of Rhythm Biosciences’ ongoing commercialisation activities, members of the team attended this year’s GPCE (General Practice Conference & Exhibition) in Sydney over the weekend, which attracted more than 1,000 GPs from across Australia. The conference provided an important opportunity to continue building clinician awareness and engagement around ColoSTAT®, with strong interest from healthcare professionals seeking additional tools to support patient triage and earlier clinical decision making. Importantly, feedback from clinicians reinforced the ongoing need for innovative screening solutions that may help address growing pressure on colonoscopy pathways across the healthcare system. Engagement from both metropolitan and regional practitioners highlights the breadth of interest as Rhythm continues executing its broader commercial strategy and market education initiatives for ColoSTAT®. #ASX #Biotech #Diagnostics #Healthcare #Commercialisation #ColorectalCancer #InvestorUpdate

The recent Federal Budget has reinforced a growing trend: medical research and healthcare innovation are increasingly being recognised as strategic priorities in Australia. This broader support for the sector is important for companies working to improve patient outcomes through earlier detection and more accessible diagnostics. At Rhythm Biosciences, we continue progressing the commercial rollout of ColoSTAT® while expanding our precision diagnostics platform focused on improving cancer detection pathways. It’s encouraging to see greater recognition of the role Australian medtech companies can play in delivering both healthcare and economic outcomes. A good overview from Stockhead below: https://lnkd.in/eXVxkXnE

Reminder: Webinar tomorrow There is still time to register for our upcoming ColoSTAT® webinar:   Smarter Triage for Bowel Cancer Symptoms The Role of ColoSTAT® in Reducing the Colonoscopy Burden Designed for General Practitioners and Gastroenterologists managing patients with bowel symptoms, this session will explore how ColoSTAT® may support risk stratification of symptomatic patients before colonoscopy referral. Presented by Dr Andrew Feber, Clinical Advisor to Rhythm Biosciences.   Date: 20 May 2026 Time: 5:30pm–6:00pm AET Register: www.colostat.com/webinar If you know a GP, gastroenterologist, or physician who may find this valuable for their patients, please share this with them. #RhythmBiosciences #RHY #ColoSTAT #BowelCancer #GeneralPractice #4Cyte #Colonoscopy #Gastroenterologists

Colorectal cancer diagnostic pathways are under increasing pressure, with many symptomatic patients facing long waits for colonoscopy. Register now for our upcoming webinar at www.colostat.com/webinar Smarter Triage for Bowel Cancer Symptoms The Role of ColoSTAT® in Reducing the Colonoscopy Burden Presented by @Dr Andrew Feber, Clinical Advisor to @Rhythm Biosciences, this session will explore how ColoSTAT®, a blood-based protein biomarker test, may support risk stratification of symptomatic patients before colonoscopy referral. This webinar is designed for General Practitioners and Gastroenterologists managing patients with bowel symptoms. Date: 20 May 2026 Time: 5:30pm–6:00pm AET To Register : www.colostat.com/webinar If you know a General Practitioner, Gastroenterologist, or physician who may find this valuable for their patients, please share this with them. #RhythmBiosciences #RHY #ColoSTAT #BowelCancer #GeneralPractice #4Cyte #Colonoscopy #Gastroenterologists